Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

被引：56

作者：

Baghaei, Kaveh ^{[1
,2
]}

Mazhari, Sogol ^{[1
]}

Tokhanbigli, Samaneh ^{[1
]}

Parsamanesh, Gilda ^{[1
]}

Alavifard, Helia ^{[1
]}

Schaafsma, Dedmer ^{[3
]}

Ghavami, Saeid ^{[4
,5
,6
,7
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Basic & Mol Epidemiol Gastrointestinal Disorders, Tehran 1985717413, Iran

[2] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran 1985717413, Iran

[3] Sci Impact, Winnipeg, MB, Canada

[4] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada

[5] Univ Manitoba, Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB R3E 0V9, Canada

[6] Univ Manitoba, Children Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB R3E 0V9, Canada

[7] Katowice Sch Technol, Fac Med, PL-40555 Katowice, Poland

来源：

DRUG DISCOVERY TODAY | 2022年 / 27卷 / 04期

关键词：

Liver diseases; Extracellular signaling; Cell phenotype; Fibrogenic myofibroblasts; Autophagy; NF-KAPPA-B; HEDGEHOG SIGNALING INHIBITOR; TGF-BETA; ANTIFIBROTIC ACTIVITY; EXTRACELLULAR-MATRIX; RECEPTOR; AUTOPHAGY; PATHWAY; ANGIOGENESIS; PDGF;

D O I：

10.1016/j.drudis.2021.12.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatic fibrosis is a manifestation of different etiologies of liver disease with the involvement of multiple mediators in complex network interactions. Activated hepatic stellate cells (aHSCs) are the central driver of hepatic fibrosis, given their potential to induce connective tissue formation and extracellular matrix (ECM) protein accumulation. Therefore, identifying the cellular and molecular pathways involved in the activation of HSCs is crucial in gaining mechanistic and therapeutic perspectives to more effectively target the disease. In addition to a comprehensive summary of our current understanding of the role of HSCs in liver fibrosis, we also discuss here the proposed therapeutic strategies based on targeting HSCs.

引用

页码：1044 / 1061

页数：18

共 166 条

[1] Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis [J].